This journal no longer participates in Medscape Publishers' Circle Program. No new articles will be republished.
Articles Available on Medscape
- Risks of Cardiovascular Diseases Associated With Dipeptidyl Peptidase-4 Inhibitors and Other Antidiabetic Drugs in Patients With Type 2 Diabetes
- Cost-Effectiveness of Screening Strategies to Detect Heart Failure in Patients With Type 2 Diabetes
- Oxidative Stress, Inflammation, Endothelial Dysfunction and Incidence of Type 2 Diabetes
- Cardiovascular Efficacy of Sitagliptin in Patients With Diabetes at High Risk of Cardiovascular Disease
- Long-term Mortality and Incidence of Cardiovascular Diseases and Type 2 Diabetes in Diabetic and Nondiabetic Obese Patients Undergoing Gastric Banding
Cardiovascular Diabetology's Latest Table of Contents
2017 - 16 (1)
- Association between obstructive sleep apnea severity and endothelial dysfunction in patients with type 2 diabetes.
- Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
- Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature.
- Clinical outcomes and glycaemic responses to different aerobic exercise training intensities in type II diabetes: a systematic review and meta-analysis.
- Subclinical left ventricular diastolic dysfunction and incident type 2 diabetes risk: the Korean Genome and Epidemiology Study.
- Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.
- Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.
- Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.
- The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction.
- Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
- Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride glucose index in normal-weight people: The Rural Chinese Cohort Study.
- Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
- Diagnostic approaches for diabetic cardiomyopathy.
- Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.
- A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
- Erratum to: Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway.
- Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.
- DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
- Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up.
- Advanced glycation end products induce brain-derived neurotrophic factor release from human platelets through the Src-family kinase activation.
- Obesity and type 2 diabetes have additive effects on left ventricular remodelling in normotensive patients-a cross sectional study.
- Inhibition of dynamin-related protein 1 protects against myocardial ischemia-reperfusion injury in diabetic mice.
- Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.
- Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study.
- The renal tubular damage marker urinary N-acetyl-β-D-glucosaminidase may be more closely associated with early detection of atherosclerosis than the glomerular damage marker albuminuria in patients with type 2 diabetes.
- Obesity, metabolic syndrome and cardiovascular prognosis: from the Partners coronary computed tomography angiography registry.
- Skin autofluorescence is associated with inappropriate left ventricular mass and diastolic dysfunction in subjects at risk for cardiovascular disease.
- A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
- The association between diabetes and dermal microvascular dysfunction non-invasively assessed by laser Doppler with local thermal hyperemia: a systematic review with meta-analysis.
- T-cadherin deficiency increases vascular vulnerability in T2DM through impaired NO bioactivity.
- Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
- Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
- Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
- Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways.
- Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study.
- Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus.
- Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy.
- Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006-2013).
- Blood pressure control in type 2 diabetic patients.
- Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome.